276 related articles for article (PubMed ID: 26250566)
1. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma.
Baraniskin A; Zaslavska E; Nöpel-Dünnebacke S; Ahle G; Seidel S; Schlegel U; Schmiegel W; Hahn S; Schroers R
Neuro Oncol; 2016 Mar; 18(3):361-7. PubMed ID: 26250566
[TBL] [Abstract][Full Text] [Related]
2. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
[TBL] [Abstract][Full Text] [Related]
3. Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients.
Kuhlmann JD; Wimberger P; Wilsch K; Fluck M; Suter L; Brunner G
Clin Chem Lab Med; 2015 Mar; 53(4):605-11. PubMed ID: 25741740
[TBL] [Abstract][Full Text] [Related]
4. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma.
Baraniskin A; Nöpel-Dünnebacke S; Ahrens M; Jensen SG; Zöllner H; Maghnouj A; Wos A; Mayerle J; Munding J; Kost D; Reinacher-Schick A; Liffers S; Schroers R; Chromik AM; Meyer HE; Uhl W; Klein-Scory S; Weiss FU; Stephan C; Schwarte-Waldhoff I; Lerch MM; Tannapfel A; Schmiegel W; Andersen CL; Hahn SA
Int J Cancer; 2013 Jan; 132(2):E48-57. PubMed ID: 22907602
[TBL] [Abstract][Full Text] [Related]
5. Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders.
Baraniskin A; Nöpel-Dünnebacke S; Schumacher B; Gerges C; Bracht T; Sitek B; Meyer HE; Gerken G; Dechene A; Schlaak JF; Schroers R; Pox C; Schmiegel W; Hahn SA
Dig Dis Sci; 2014 Jul; 59(7):1436-41. PubMed ID: 24482036
[TBL] [Abstract][Full Text] [Related]
6. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
[TBL] [Abstract][Full Text] [Related]
7. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer.
Kuhlmann JD; Baraniskin A; Hahn SA; Mosel F; Bredemeier M; Wimberger P; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Jan; 60(1):206-13. PubMed ID: 24212085
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
[TBL] [Abstract][Full Text] [Related]
9. CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma.
Viaccoz A; Ducray F; Tholance Y; Barcelos GK; Thomas-Maisonneuve L; Ghesquières H; Meyronet D; Quadrio I; Cartalat-Carel S; Louis-Tisserand G; Jouanneau E; Guyotat J; Honnorat J; Perret-Liaudet A
Neuro Oncol; 2015 Nov; 17(11):1497-503. PubMed ID: 26014047
[TBL] [Abstract][Full Text] [Related]
10. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic role and dynamic changes in cerebrospinal fluid neopterin during treatment of patients with primary central nervous system lymphoma.
Geng M; Xiao H; Liu J; Song Y; Fu P; Cheng X; Zhang J; Wang G
Cancer Med; 2018 Aug; 7(8):3889-3898. PubMed ID: 29982995
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma.
Baraniskin A; Kuhnhenn J; Schlegel U; Schmiegel W; Hahn S; Schroers R
J Neurooncol; 2012 Sep; 109(2):239-44. PubMed ID: 22729947
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
[TBL] [Abstract][Full Text] [Related]
15. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of CSF soluble CD27 for primary central nervous system lymphoma in immunocompetent patients.
Murase S; Saio M; Andoh H; Takenaka K; Shinoda J; Nishimura Y; Sakai N; Takami T
Neurol Res; 2000 Jul; 22(5):434-42. PubMed ID: 10935213
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
Li J; Tang X; Luo X; Liu L; Li D; Yang L
Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
[TBL] [Abstract][Full Text] [Related]
19. Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors.
Downs BM; Ding W; Cope LM; Umbricht CB; Li W; He H; Ke X; Holdhoff M; Bettegowda C; Tao W; Sukumar S
Clin Epigenetics; 2021 May; 13(1):104. PubMed ID: 33952317
[TBL] [Abstract][Full Text] [Related]
20. Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.
Roth P; Keller A; Hoheisel JD; Codo P; Bauer AS; Backes C; Leidinger P; Meese E; Thiel E; Korfel A; Weller M
Eur J Cancer; 2015 Feb; 51(3):382-90. PubMed ID: 25534293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
